866-997-4948(US-Canada Toll Free)

United States Type 1 Diabetes Drugs Market Report 2017

Published By :

QYResearch

Published Date : Feb 2017

Category :

Pharmaceutical

No. of Pages : 106 Pages

Notes:
Sales, means the sales volume of Type 1 Diabetes Drugs
Revenue, means the sales value of Type 1 Diabetes Drugs

This report studies sales (consumption) of Type 1 Diabetes Drugs in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering
Novo Nordisk
Sanofi
Eli Lily
AstraZeneca
Astellas Pharma
Merck
Perle Biosciences
Pfizer
Merrion Pharmaceutical
Boehringer Ingelheim
XOMA
Osiris Therapeutics
GlaxoSmithKline
Generex Biotechnology
Gan & Lee Pharmaceuticals
Adocia
Baxalta
Tolerio

Market Segment by States, covering
California
Texas
New York
Florida
Illinois
Split by product types, with sales, revenue, price, market share and growth rate of each type, can be divided into
Fast-Acting Insulin
Intermediate-Acting Insulin
Long-Acting Insulin
Other
Split by applications, this report focuses on sales, market share and growth rate of Type 1 Diabetes Drugs in each application, can be divided into
Hospitals
Clinics

Table of Contents

United States Type 1 Diabetes Drugs Market Report 2017
1 Type 1 Diabetes Drugs Overview
1.1 Product Overview and Scope of Type 1 Diabetes Drugs
1.2 Classification of Type 1 Diabetes Drugs
1.2.1 Fast-Acting Insulin
1.2.2 Intermediate-Acting Insulin
1.2.3 Long-Acting Insulin
1.2.4 Other
1.3 Application of Type 1 Diabetes Drugs
1.3.1 Hospitals
1.3.2 Clinics
1.4 United States Market Size Sales (Volume) and Revenue (Value) of Type 1 Diabetes Drugs (2012-2022)
1.4.1 United States Type 1 Diabetes Drugs Sales and Growth Rate (2012-2022)
1.4.2 United States Type 1 Diabetes Drugs Revenue and Growth Rate (2012-2022)

2 United States Type 1 Diabetes Drugs Competition by Manufacturers
2.1 United States Type 1 Diabetes Drugs Sales and Market Share of Key Manufacturers (2015 and 2016)
2.2 United States Type 1 Diabetes Drugs Revenue and Share by Manufactures (2015 and 2016)
2.3 United States Type 1 Diabetes Drugs Average Price by Manufactures (2015 and 2016)
2.4 Type 1 Diabetes Drugs Market Competitive Situation and Trends
2.4.1 Type 1 Diabetes Drugs Market Concentration Rate
2.4.2 Type 1 Diabetes Drugs Market Share of Top 3 and Top 5 Manufacturers
2.4.3 Mergers & Acquisitions, Expansion

3 United States Type 1 Diabetes Drugs Sales (Volume) and Revenue (Value) by States (2012-2017)
3.1 United States Type 1 Diabetes Drugs Sales and Market Share by States (2012-2017)
3.2 United States Type 1 Diabetes Drugs Revenue and Market Share by States (2012-2017)
3.3 United States Type 1 Diabetes Drugs Price by States (2012-2017)

4 United States Type 1 Diabetes Drugs Sales (Volume) and Revenue (Value) by Type (2012-2017)
4.1 United States Type 1 Diabetes Drugs Sales and Market Share by Type (2012-2017)
4.2 United States Type 1 Diabetes Drugs Revenue and Market Share by Type (2012-2017)
4.3 United States Type 1 Diabetes Drugs Price by Type (2012-2017)
4.4 United States Type 1 Diabetes Drugs Sales Growth Rate by Type (2012-2017)

5 United States Type 1 Diabetes Drugs Sales (Volume) by Application (2012-2017)
5.1 United States Type 1 Diabetes Drugs Sales and Market Share by Application (2012-2017)
5.2 United States Type 1 Diabetes Drugs Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 United States Type 1 Diabetes Drugs Manufacturers Profiles/Analysis
6.1 Novo Nordisk
6.1.1 Company Basic Information, Manufacturing Base and Competitors
6.1.2 Type 1 Diabetes Drugs Product Type, Application and Specification
6.1.2.1 Product A
6.1.2.2 Product B
6.1.3 Novo Nordisk Type 1 Diabetes Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
6.1.4 Main Business/Business Overview
6.2 Sanofi
6.2.2 Type 1 Diabetes Drugs Product Type, Application and Specification
6.2.2.1 Product A
6.2.2.2 Product B
6.2.3 Sanofi Type 1 Diabetes Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
6.2.4 Main Business/Business Overview
6.3 Eli Lily
6.3.2 Type 1 Diabetes Drugs Product Type, Application and Specification
6.3.2.1 Product A
6.3.2.2 Product B
6.3.3 Eli Lily Type 1 Diabetes Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
6.3.4 Main Business/Business Overview
6.4 AstraZeneca
6.4.2 Type 1 Diabetes Drugs Product Type, Application and Specification
6.4.2.1 Product A
6.4.2.2 Product B
6.4.3 AstraZeneca Type 1 Diabetes Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
6.4.4 Main Business/Business Overview
6.5 Astellas Pharma
6.5.2 Type 1 Diabetes Drugs Product Type, Application and Specification
6.5.2.1 Product A
6.5.2.2 Product B
6.5.3 Astellas Pharma Type 1 Diabetes Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
6.5.4 Main Business/Business Overview
6.6 Merck
6.6.2 Type 1 Diabetes Drugs Product Type, Application and Specification
6.6.2.1 Product A
6.6.2.2 Product B
6.6.3 Merck Type 1 Diabetes Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
6.6.4 Main Business/Business Overview
6.7 Perle Biosciences
6.7.2 Type 1 Diabetes Drugs Product Type, Application and Specification
6.7.2.1 Product A
6.7.2.2 Product B
6.7.3 Perle Biosciences Type 1 Diabetes Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
6.7.4 Main Business/Business Overview
6.8 Pfizer
6.8.2 Type 1 Diabetes Drugs Product Type, Application and Specification
6.8.2.1 Product A
6.8.2.2 Product B
6.8.3 Pfizer Type 1 Diabetes Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
6.8.4 Main Business/Business Overview
6.9 Merrion Pharmaceutical
6.9.2 Type 1 Diabetes Drugs Product Type, Application and Specification
6.9.2.1 Product A
6.9.2.2 Product B
6.9.3 Merrion Pharmaceutical Type 1 Diabetes Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
6.9.4 Main Business/Business Overview
6.10 Boehringer Ingelheim
6.10.2 Type 1 Diabetes Drugs Product Type, Application and Specification
6.10.2.1 Product A
6.10.2.2 Product B
6.10.3 Boehringer Ingelheim Type 1 Diabetes Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
6.10.4 Main Business/Business Overview
6.11 XOMA
6.12 Osiris Therapeutics
6.13 GlaxoSmithKline
6.14 Generex Biotechnology
6.15 Gan & Lee Pharmaceuticals
6.16 Adocia
6.17 Baxalta
6.18 Tolerio

7 Type 1 Diabetes Drugs Manufacturing Cost Analysis
7.1 Type 1 Diabetes Drugs Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Price Trend of Key Raw Materials
7.1.3 Key Suppliers of Raw Materials
7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.2.1 Raw Materials
7.2.2 Labor Cost
7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Type 1 Diabetes Drugs

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
8.1 Type 1 Diabetes Drugs Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Type 1 Diabetes Drugs Major Manufacturers in 2015
8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
9.1 Marketing Channel
9.1.1 Direct Marketing
9.1.2 Indirect Marketing
9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
9.2.1 Pricing Strategy
9.2.2 Brand Strategy
9.2.3 Target Client
9.3 Distributors/Traders List

10 Market Effect Factors Analysis
10.1 Technology Progress/Risk
10.1.1 Substitutes Threat
10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 United States Type 1 Diabetes Drugs Market Forecast (2017-2022)
11.1 United States Type 1 Diabetes Drugs Sales, Revenue Forecast (2017-2022)
11.2 United States Type 1 Diabetes Drugs Sales Forecast by Type (2017-2022)
11.3 United States Type 1 Diabetes Drugs Sales Forecast by Application (2017-2022)
11.4 Type 1 Diabetes Drugs Price Forecast (2017-2022)

12 Research Findings and Conclusion

13 Appendix
Methodology
Analyst Introduction
Data Source

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *